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Abstract
Propionibacterium species rarely cause infective endocarditis. When identiﬁed in blood cultures, they may be inappropriately disregarded as
skin ﬂora contaminants. The purpose of this study was to characterize the clinical presentation and management of endocarditis due to Propi-
onibacterium species. All cases of endocarditis due to Propionibacterium species that were treated at the Mayo Clinic, Rochester, USA were
retrospectively reviewed, and the English language medical literature was searched for all previously published reports. Seventy cases, which
included eight from the Mayo Clinic, were identiﬁed (clinical details were available for only 58 cases). The median age of patients was 52 years,
and 90% were males. In 79% of the cases, the infection involved prosthetic material (39 prosthetic valves, one left ventricular Teﬂon patch,
one mitral valve ring, one pulmonary artery prosthetic graft, three pacemakers, and one deﬁbrillator). Blood cultures were positive in 62% of
cases. All 22 cases with negative blood cultures were microbiologically conﬁrmed by either positive valve tissue cultures (n = 21) or molecular
methods (n = 1). Endocarditis was complicated by abscess formation in 36% of cases. The majority (81%) of patients underwent surgery,
either for valve replacement and debridement of a cardiac abscess, or removal of an infected device. Crude in-hospital mortality was 16%. The
median duration of postoperative antibiotic treatment was 42 days. Patients were commonly treated with a penicillin derivative alone or in
combination with gentamicin. On the basis of the above data, it is recommended that infective endocarditis should be strongly suspected when
Propionibacterium species are isolated frommultiple blood cultures, particularly in the presence of a cardiovascular device.
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Introduction
Propionibacterium species are micro-aerophilic, non-spore-
forming, pleomorphic, Gram-positive coccobacilli that are
ubiquitous; they are constituents of the normal human skin
microﬂora. Major species include Propionibacterium acnes, Propi-
onibacterium granulosum and Propionibacterium propionicum.
When identiﬁed in blood cultures, propionibacteria are often
regarded as skin contaminants. Although generally non-patho-
genic, Propionibacterium species have been implicated in serious
infections, including brain abscesses, osteomyelitis, endoph-
thalmitis, cerebrospinal shunt infections, subdural empyema,
parotid and dental infections, and infective endocarditis [1]. In
the case of endocarditis, Propionibacterium species usually cause
prosthetic valve infection.
Propionibacterium species are probably underestimated and
under-reported, but potentially serious, causes of infective
endocarditis. Thus, both our institutional records and the
published English language medical literature that describes
cases of infective endocarditis due to Propionibacterium spe-
cies were reviewed.
Patients and Methods
All cases of Propionibacterium endocarditis managed at the
Mayo Clinic, Rochester, USA were retrospectively reviewed.
Cases of Propionibacterium endocarditis were identiﬁed from
a prospective database of endocarditis cases maintained by
the Division of Infectious Diseases [2] from 1967 to 2005,
and from the computerized diagnostic index of the Mayo
Clinic. Patients who consented to the use of their medical
records for research were included in the study, following
approval of the protocol by the Mayo Clinic Institutional
Review Board.
All previously published case reports of Propionibacterium
endocarditis were reviewed. The English language medical
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literature was searched using the online bibliographic data-
bases of the National Library of Medicine (MEDLINE, Pub-
Med). Search terms included Propionibacterium, P. acnes,
P. granulosum, Propionibacterium species, endocarditis, infec-
tion, infective endocarditis, prosthetic valve, pacemaker, and
implantable cardioverter-deﬁbrillator. An extensive bibliogra-
phy search of the articles identiﬁed through the MEDLINE
and PubMed was also performed.
Case deﬁnition
It is difﬁcult to make an accurate count of valid cases of
endocarditis due to Propionibacterium species as described
in the earlier literature, because of inconsistencies in the
nomenclature and insufﬁcient microbiological characteriza-
tion of the infecting organisms. Only cases that fulﬁlled
the modiﬁed Duke criteria [3] for diagnosis of deﬁnite
infective endocarditis were included in the review. Cases
with a single positive blood culture for Propionibacterium
species only, or positive valve tissue cultures in the
absence of histopathological evidence of endocarditis, were
excluded.
Case series
Demographics, clinical presentation and management of eight
patients with endocarditis due to Propionibacterium who were
treated at the Mayo Clinic are summarized in Table 1.
Illustrative case (no. 5, Mayo series)
The following case illustrates how initial blood cultures
positive for Propionibacterium species may be disregarded as
contaminants from skin ﬂora.
A 64-year-old male was admitted to the referring hospital
for evaluation of a 2-month history of intermittent fever, rig-
ors, and fatigue. The patient underwent an aortic valve (AV)
homograft replacement in 1988 for bicuspid AV; he subse-
quently developed enterococcal endocarditis in 2000, and
required bioprosthetic AV revision in 2002.
Hospital evaluation for endocarditis, including blood cul-
tures and a transoesophageal echocardiogram (TEE), were
negative. The patient received a short course of empirical
treatment with ceftriaxone and vancomycin, which was dis-
continued because of the absence of a speciﬁc diagnosis, and
the patient was discharged. Following discharge, the patient
had a recurrence of symptoms, and was re-admitted
2 months later. Blood cultures were obtained, and a repeat
TEE showed a dehisced prosthetic AV with perivalvular leak.
Empirical treatment with vancomycin and levoﬂoxacin was
initiated, and the patient was transferred to the Mayo Clinic
2 days following admission.
Upon arrival, the patient was febrile (38.3C) but was hae-
modynamically stable. Physical examination revealed a loud
(grade IV/VI) systolic ejection murmur, and coarse crackles
in bilateral lung bases. The peripheral leukocyte count was
TABLE 1. Summary of data concerning eight patients with Propionibacterium acnes endocarditis—Mayo Clinic experience
Case
no.
Age/
gender
Predisposing/comorbid
conditions
Clinical
presentation
Echocardiographic
ﬁndings Treatment Outcome (FUP)
1 26/F RHD, Carpentier–Edwards
MV replacement
Fatigue, anaemia
()BC/+VC)a
MV regurgitation Vancomycin · 4 weeks, surgery
for perivalvular leak and
abscess debridement
Cured (1 year)
2 55/M Starr–Edwards ball
prosthetic MV (re-do
secondary to leak)
Fever, shortness of
breath, weight loss,
sweating (+BC/+VC)a
MV regurgitation Cefazolin · 4 weeks, surgery
for valve replacement and
abscess debridement
Cured (11 years)
3 76/M Carpentier–Edwards
prosthetic AV
Shortness of breath
()BC/+VC)a
AV regurgitation,
perivalvular abscess,
aortoventricular ﬁstula
Vancomycin + ceftriaxone
· 4 weeks, surgery for
abscess debridement
Cured (5 years)
4 78/M RHD, Carpentier–Edwards
prosthetic AV
Fever, shortness of
breath, syncope
()BC/+VC)a
AV regurgitation,
periprosthetic leak
Vancomycin · 6 weeks,
surgery for valve
replacement
Died of infection
5 64/M Bioprosthetic AV
replacement for
bicuspid valve
Fever, rigors, fatigue,
positive Q-fever
serology (+BC/+VC)a
Prosthetic valve
dehiscence,
perivalvular leak
Ceftriaxone–penicillin
· 6 weeks, surgery for
perivalvular abscess
debridement and valve
replacement
Cured (2 years)
6 80/M Prosthetic AV/MV Right knee septic
arthritis (+BC/+VC)a
MV vegetation and
regurgitation
Ceftriaxone · 6 weeks
+ gentamicin · 2 weeks,
no surgery
Cured
(18 months)
7 61/M PPM Fever, malaise, fatigue,
sweating (+BC/+VC/+
PPM lead cultures)a
TV and PPM lead
vegetation
Cefazolin · 4 weeks. TV repair
and PPM leads extraction
Cured (1 month)
8 46/M ICD, CHF, non-Hodgkins
lymphoma
Fever, fatigue, malaise,
hypotension, ICD
pocket infection
()BC/+ICD lead and
pocket cultures)a
ICD lead vegetation Vancomycin · 4 weeks,
percutaneous ICD lead
extraction
Cured
(18 months)
+, positive; ), negative; AV, aortic valve; BC, blood culture; CHF, congestive heart failure; FUP, follow-up period; ICD, implantable cardioverter-deﬁbrillator; MV, mitral valve;
PPM, permanent pacemaker; RHD, rheumatic heart disease; TV, tricuspid valve; VC, valve culture.
aRefers to P. acnes cultures.
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normal, and the erythrocyte sedimentation rate was 24 mm/h.
Repeat blood cultures were performed, and empirical treat-
ment with ampicillin–sulbactam and gentamicin was initiated.
Blood cultures from the referring hospital were negative after
72 h of incubation, and the procedure for culture-negative
endocarditis was initiated.
Serological studies gave negative results for Brucella spe-
cies, Francisella tularensis, Coccidioides, Cryptococcus, Histoplas-
ma, Borrelia burgdorferi, and Legionella. However, Coxiella
burnetii serological studies revealed an IgG phase 1 titre of
1 : 1024, an IgM phase I titre <1 : 16, an IgG phase II titre of
1 : 2048, and IgM phase II titre <1 : 16. These ﬁndings were
consistent with acute C. burnetii [4,5]. The patient reported
exposure to farm animals (sheep) 7 months prior to illness.
Ongoing antibiotic treatment was discontinued, and treat-
ment with oral doxycycline and hydroxychloroquine was
started.
Blood cultures obtained at the referring hospital were
reported to have grown Gram-positive rods in the anaerobic
bottles on day 6 of incubation, and these were subsequently
identiﬁed as P. acnes. However, with convincing serological
evidence of Q-fever endocarditis, these cultures were disre-
garded as skin contaminants. The blood cultures obtained at
the Mayo Clinic remained negative.
A repeat TEE showed a large pseudo-aneurysm of the
posterior aortic root with severe paraprosthetic aortic
regurgitation and an unsupported AV posteriorly. The
patient underwent surgery, and intra-operative ﬁndings indi-
cated disruption of the valve annulus, pseudo-aneurysm at
the pericardial–aortic anastomosis, and a peri-annular
abscess. Abscess cavities were debrided, and the infected
prosthetic AV was replaced with a homograft. Valvular
pathology showed a 1.6-cm vegetation and active endocardi-
tis with numerous Gram-positive coccobacilli (Fig. 1). AV tis-
sue cultures grew P. acnes. The isolate was susceptible to
penicillin and clindamycin according to in vitro testing. Repeat
C. burnetii serological studies showed an IgG phase 1 titre of
1 : 16 384 (four-fold rise as compared to initial testing), an
IgM phase I titre >1 : 16, an IgG phase II titre of 1 : 4096,
and an IgM phase II titre <1 : 16. Unfortunately, the valve
was not sent for C. burnetii culture or PCR.
The postoperative course was complicated by nosocomial
pneumonia, which required broad-spectrum antibiotics.
Following improvement, treatment with aqueous crystalline
penicillin G (15 million units per day) was given for 6 weeks
(adjusted for renal function), followed by suppression ther-
apy with oral penicillin V (500 mg twice daily) for P. acnes
endocarditis. Treatment with oral doxycycline (100 mg twice
daily) and hydroxychloroquine (200 mg three times daily)
was continued, to complete an 18-month course, and this
was followed by lifelong suppressive therapy for Q-fever
with oral doxycycline (100 mg twice daily). Repeat C. burnetii
serological studies that were performed 3 months following
discharge showed an IgG phase 1 titre of 1 : 2048 and an
IgG phase II titre of 1 : 512. C. burnetii serological results
obtained 6 months following discharge showed an IgG
phase 1 titre of 1 : 1024 and an IgG phase II titre of 1 : 512.
The patient was doing well at the last follow-up visit 2 years
later.
Results
Seventy cases of Propionibacterium endocarditis were
identiﬁed through a search of the English language medical
literature and the Mayo Clinic institutional database [6–35].
However, clinical details were available for only 58 cases
(including eight patients from our series) [6,8–12,14–35] to
classify them as ‘deﬁnite’ endocarditis using the modiﬁed
Duke criteria [3]. Demographic characteristics of these 58
cases are summarized in Table 2.
The median age of the patients at the time of presentation
was 52 years (range 15–80 years), and 90% were males.
Endocarditis involved a prosthetic cardiac device in 79% of
cases (Table 2), and prosthetic valve endocarditis (39, 67%)
was the most common presentation. Among the 12 patients
who did not have a prosthetic device, eight had a docu-
mented history of an abnormal native heart valve (stenosis,
regurgitation, or degenerative disease) prior to developing
endocarditis. Congestive heart failure (16%) and diabetes
mellitus (8%) were other commonly reported comorbid con-
ditions (Table 2).
FIG. 1. Aortic valve bioprosthesis, with one vegetation (up to
1.6 cm in greatest dimension) with active infective endocarditis. The
image shows blue clumps of Gram-positive bacilli.
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The clinical presentation of patients is summarized in
Table 3. The majority (75%) had systemic symptoms at initial
presentation that included fever, malaise, fatigue, cough, and/
or shortness of breath. The median time from symptom
onset to diagnosis of endocarditis was 4 weeks. Blood
cultures were positive in 36 (62%) cases. Among 22 patients
with negative blood cultures, Propionibacterium species were
identiﬁed according to valve tissue cultures (21 patients) or
molecular methods (one isolate, 16S rRNA gene PCR
ampliﬁcation) [8]. The median time to blood or tissue
culture positivity was 7 days. However, in four cases, it took
10–14 days for blood cultures to become positive
[10,27,29,31]. P. acnes was the most commonly isolated
species (64% cases). P. granulosum was identiﬁed in two
patients, both of whom had native valve endocarditis [6,9].
AVs were the most common sites of vegetation forma-
tion (71%), followed by mitral (24%) and tricuspid (3%)
valves. One patient had infection of a prosthetic shunt,
implanted between the pulmonary artery and right ventricle,
that was complicated by pseudo-aneurysm formation [8].
Myocardial abscesses were reported in 21 (36%) patients,
and the majority (18, 86%) involved a prosthetic cardiac
device. Peripheral emboli were reported in nine (16%) cases
(eight aortic valve, and one mitral valve) and eight of these
were in patients with prosthetic valve endocarditis. Meta-
static foci of infection included septic arthritis involving the
knee (n = 1), splenic infarction (n = 3), renal abscess forma-
tion (n = 1), pancreatic abscess formation (n = 1), and
peripheral mycotic aneurysms (n = 4). Brain emboli
occurred in six patients (four of whom also had peripheral
emboli) [14,16,17,20] and only in those with prosthetic AV
endocarditis.
The majority of patients (47, 81%) underwent surgery,
in addition to prolonged antimicrobial treatment; the
remaining 11 (19%) patients were managed with antibiotics
alone. Details of antimicrobial treatment were available for
only 44 patients. Twenty patients (45%) were treated with
a b-lactam or glycopeptide plus aminoglycoside, and the
remaining 24 (55%) patients received monotherapy (b-lac-
tams or glycopeptides). The median duration of antibiotics
was 42 days (interquartile range 28–42 days). Five patients
received chronic suppressive therapy with amoiycillin or
clindamycin (for 3–6 months) after prosthetic valve
replacement and a 6–8-week course of intravenous antibi-
otics [8,15,32,35].
Overall mortality in patients with Propionibacterium endo-
carditis was 16% (nine cases; seven patients with prosthetic
valve involvement, and two with native valve infection).
Demographic and clinical characteristics of these patients are
summarized in Table 4 (excluding case no. 4 from the Mayo
series, which is listed in Table 1). Three deaths occurred in
patients who were managed conservatively with antibiotics
alone; two of these patients died within 72 h of hospitaliza-
tion. Six patients died despite undergoing combined medical
and surgical therapy.
TABLE 2. Clinical characteristics of patients with Propioni-
bacterium endocarditis (Mayo Clinic series and review of the
literature, n = 58)
Age
Median (IQR) years 52 (40–61) years
Range 15–80 years
Gender
Male 52 (90%)
Female 6 (10%)
Predisposing conditions/comorbid conditions
Prosthetic heart valve 39 (67%)
Permanent pacemaker/deﬁbrillator 4 (7%)
Other prosthetic devicesa 3 (5%)
History of rheumatic heart disease 10 (17%)
Congestive heart failure 9 (16%)
Diabetes mellitus 5 (8%)
Immunocompromised 3 (5%)
History of endocarditis 3 (5%)
IQR, interquartile range.
aInclude one each of ventricular Teﬂon patch, mitral prosthetic valve ring, and
prosthetic pulmonary artery graft.
TABLE 3. Clinical presentation, microbiology and compli-
cations in patients with Propionibacterium endocarditis
(Mayo Clinic series and review of the literature, n = 58a).
Variable Number (%)a
Clinical presentation
Time from valvular replacement/device insertion
to endocarditis, median (range), years
4 years
(3 weeks to 23 years)
Time from symptom onset to diagnosis,
median (range) weeks
4 (1–32) weeks
Systemic symptomsb (n = 40)c 30 (75%)
Leukocytosis (n = 23)c 13 (57%)
Positive blood culturesd 36 (62%)
Positive valve tissue/device lead cultures 28 (48%)
Time to positive blood/valve culture, median
(range), days
7 (4–14) days
Histopathological conﬁrmation of valve infection 23 (40%)
Microbiology
Propionibacterium acnes 37 (64%)
Propionibacterium granulosum 2 (3%)
Propionibacterium species (further identiﬁcation
not available)
19 (33%)
Complications
Peripheral emboli 9 (16%)
Brain emboli 6 (10%)
Myocardial abscess 21 (36%)
Valvular insufﬁciency 30 (52%)
Crude in-hospital mortality 9 (16%)
Valvular involvement
Aortic valve 41 (71%)
Mitral valve 14 (24%)
Tricuspid valve 2 (3%)
aUnless otherwise speciﬁed.
bIncluding fever, chills, malaise, fatigue, myalgias, and weight loss.
cn, number of cases for which data were available.
dTwo or more positive blood cultures with Propionibacterium species were
reported in 33 cases. In three patients with single positive blood cultures, Propi-
onibacterium endocarditis was conﬁrmed by histopathology (two cases) and posi-
tive electrode lead tip culture (one case with pacemaker-associated
endocarditis).
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Two patients suffered relapsing infection [20,27]. Both
patients had prosthetic mitral valve endocarditis without evi-
dence of cardiac abscess or heart failure, and both were
managed conservatively with antibiotics alone. One patient
was a 41-year-old male who was initially treated with a
6-week course of ampicillin and gentamicin [27]. He relapsed
5 months later, and received another 4-week course of
intravenous penicillin and gentamicin without surgical
intervention. The patient remained free of infection during
the next 18 months of follow-up. The other patient was a
52-year-old male who was treated with a 6-week course of
a b-lactam antibiotic and doxycycline, starting at initial
presentation [20]. This patient had three episodes of
relapsing endocarditis over the next 4 years but survived.
DISCUSSION
The majority of patients with Propionibacterium endocarditis
were middle-aged men with prosthetic cardiac devices. In
the current review, 79% of cases involved a prosthetic heart
valve, permanent pacemaker, implantable cardioverter-
deﬁbrillator, or prosthetic valve ring. The propensity of
propionibacteria to cause prosthetic valve endocarditis may
be due to their ability to adhere to foreign body surfaces
and produce bioﬁlm [36,37]. Native valve endocarditis due
to Propionibacterium species is uncommon, and involved
abnormal native valves (secondary to rheumatic heart disease
or degenerative changes) in 67% of cases in this study. A
preponderance of men among patients with Propionibacterium
endocarditis is consistent with similar trends observed in
patients with endocarditis involving infection of a prosthetic
valve due to Staphylococcus aureus [38] and infections associ-
ated with percutaneous vascular closure devices [39] or
endocarditis associated with a permanent pacemaker or
implantable cardioverter-deﬁbrillator [40,41]. Whether this
prevalence of infection in males is due to a higher rate of
implantation of prosthetic devices or, rather, other comorbid
conditions remains unclear.
Infection of a prosthetic valve probably results from con-
tamination at the time of the implantation, as propionibacte-
ria form part of the normal human skin ﬂora. However, in
cases with very delayed presentations (up to 23 years after
valve surgery) [20], endocarditis most likely occurred due to
bacteraemia from a distant focus and secondary seeding of
the prosthetic valves. Propionibacteria form part of the nor-
mal human oropharyngeal ﬂora [42,43] and bacteraemia may
result from invasive dental procedures, a pathogenesis mech-
anism similar to that of endocarditis due to viridans group
streptococci.
The diagnosis of Propionibacterium endocarditis may be
delayed or difﬁcult to conﬁrm, for several reasons. First,
endocarditis may develop several years after valve replace-
ment surgery. Second, blood cultures may be negative in
up to one-third of cases (38% of cases in the present
study had negative blood cultures). Third, propionibacteria
grown in blood cultures may be regarded as contaminants.
Case no. 5 from the present series (Table 1) is one
example where blood cultures positive for P. acnes from a
referring institution were regarded as representing contam-
inants, and a search for culture-negative endocarditis was
initiated. Fourth, blood cultures may require longer incuba-
tion periods (up to 14 days) [27], and may be reported
as negative if blood culture bottles are incubated for only
5 days, which is currently a common practice in many
microbiology laboratories. In cases of suspected endocardi-
tis, incubation of blood (aerobic and anaerobic) and valve
tissue cultures should be extended to 14 days if they
TABLE 4. Summary of data concerning patients who died with Propionibacterium endocarditisa
References
Age/
gender Valve
Cardiac
abscess Emboli Antibiotics Surgery Comments
Clayton et al. [12] 43/M Prosthetic AV Yes Peripheral Vanc, Rif Yes Patient could not be weaned off CPB and died
on postoperative day 1
Clayton et al. [12] 56/F Native MV No No b-Lactam, AG, Rif Yes Postoperative course complicated by
Staphylococcus aureus sternal osteomyelitis,
sepsis, and renal failure
Clayton et al. [12] 67/M Native MV No No Vanc, AG, Rif No Patient died of sepsis and renal failure. Positive blood
cultures reported after death
Huynh et al. [17] 46/M Prosthetic AV Yes Peripheral, cerebral Vanc, AG, Rif Yes Patient died from rupture of splenic artery mycotic
aneurysm on postoperative day 10
Lalani et al. [20] 52/M Prosthetic valve No No NA Yes NA
Lalani et al. [20] 75/M Prosthetic AV Yes Cerebral b-Lactam, AG, Vanc No NA
McFadden et al. [24] 52/M Prosthetic AV Yes Peripheral b-Lactam Yes Renal, splenic and multiple peripheral vascular
infarcts on autopsy. Patient could not be
weaned off CPB
Wison et al. [34] 57/M Prosthetic AV No No N/A No Patient died due to PV dehiscence on day 3 of
hospitalization
AG, aminoglycoside; AV, aortic valve; CPB, cardiopulmonary bypass machine; MV, mitral valve; NA, not available; PV, prosthetic value; Rif, rifampin; Vanc, vancomycin.
aExcluding case no. 4 from the Mayo series included in Table 1.
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remain negative in the ﬁrst week, and if no alternative
diagnosis is established.
It is well recognized that valve tissue cultures can be con-
taminated during the removal and processing of specimens,
and Propionibacterium species have been identiﬁed as valve
culture contaminants [44–46]. If surgery is performed, valve
tissue specimens should be sent for both histopathological
examination and culture to conﬁrm the diagnosis. All cases
of Propionibacterium endocarditis included in the present
study (Mayo series and literature review) were conﬁrmed by
a combination of blood culture, valve culture and/or histo-
pathological examination using the modiﬁed Duke criteria
[3]. Propionibacterium endocarditis was conﬁrmed by histo-
pathological demonstration of Gram-positive coccobacilli in
cases with positive valve cultures only (negative blood cul-
tures). However, histopathological conﬁrmation of Propioni-
bacterium endocarditis was not available in four cases that
were diagnosed with valve tissue cultures (n = 3) or PCR
(n = 1) only. It is possible that positive valve tissue cultures
or PCR in these four cases could be due to contamination of
specimens during surgical removal or sample processing.
Complications of Propionibacterium endocarditis were
more frequent in cases with prosthetic valve infection than
in those with native valve infection. Myocardial abscess was
reported in 46% (18/39) of cases of prosthetic valve endo-
carditis, as compared to 25% in cases of native valve endo-
carditis (3/12). Similarly, most (89%) cases of peripheral
emboli (eight of nine patients) and all six cases (100%) of
cerebral emboli occurred in patients with prosthetic valve
endocarditis.
There was one reported case of rapidly progressive cresc-
entic glomerulonephritis and renal failure associated with
P. acnes tricuspid valve endocarditis [19]. A diagnosis of
glomerulonephritis was conﬁrmed by renal biopsy. The patient
was treated with a 2-week course of low-dose corticosteroids
and a 6-week course of intravenous penicillin G. Full recovery
of renal function occurred during the follow-up period.
Overall in-hospital mortality in the present study was 16%
(nine cases). However, there was no signiﬁcant difference in
mortality rate between prosthetic valve endocarditis (7/39,
18%) and that due to native valve infection (2/12, 17%).
Indications for surgical intervention in patients with
Propionibacterium endocarditis are similar to those for
endocarditis due to other pathogens [47]. As most of the pub-
lished data consist of case reports or small case series, there
are no clear guidelines regarding management of
Propionibacterium endocarditis. In general, patients are treated
with a 6-week course of a b-lactam antibiotic, alone or in com-
bination with aminoglycosides. Because of the limited and
uncontrolled nature of this study, a comparison of outcomes
with single vs. combination therapy cannot be made. Vancomy-
cin is generally used in patients who are allergic or intolerant
to b-lactam agents. Rifampin use has been increasingly
reported in recent cases of Propionibacterium prosthetic valve
endocarditis, possibly to take advantage of its bioﬁlm-penetrat-
ing ability [8,12,17,25]. Resistance of Propionibacterium isolates
to penicillin is extremely rare, and only one case of a penicillin-
resistant strain causing endocarditis has been reported [23].
Conclusion
Propionibacterium endocarditis should be strongly considered
in patients with blood cultures that yield this organism. The
clinical signiﬁcance of the culture results should not be dis-
counted immediately and the ﬁndings relegated to a ‘contam-
inant’ category. This is particularly relevant for male patients
who have either underlying cardiac medical devices or
abnormal native cardiac valves. Because many of these
patients require surgical intervention for cure, it is impera-
tive that resected cardiac tissue undergo both microbiologi-
cal and histopathological examination to further support a
diagnosis of endocarditis due to Propionibacterium species.
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